BEST PRACTICES AND KEY CHALLENGES IN COST-EFFECTIVENESS MODELLING OF MULTIPLE SCLEROSIS THERAPIES

被引：0
|
作者：
Smith, N. [1 ]
Beckerman, R. [1 ]
机构：
[1] CBPartners, New York, NY USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.540
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND3
引用
收藏
页码：A809 / A809
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF FAMPRIDINE FOR MULTIPLE SCLEROSIS TREATMENT IN CHINA
    Zhao, X.
    Yang, H.
    Zhao, J.
    Wei, T.
    Liu, J.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S413 - S413
  • [42] Cost, effectiveness and cost-effectiveness of therapies in acute myocardial infarction
    Greene, RJ
    Thornton, BA
    Arora, RR
    [J]. CIRCULATION, 1997, 96 (08) : 1009 - 1009
  • [43] Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Patients with Highly Active Multiple Sclerosis - Swedish Perspective
    O'Day, Ken
    Deniz, Baris
    Meyer, Kellie
    [J]. NEUROLOGY, 2012, 78
  • [44] ROVS - THE KEY IS COST-EFFECTIVENESS
    SAUNDERS, E
    [J]. OIL & GAS JOURNAL, 1986, 84 (40) : 49 - 52
  • [45] COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE
    Petropoulos, A.
    Cooney, P.
    Patidar, M.
    Gudala, K.
    Tiwari, S.
    Brennan, R.
    Kapsogeorgiou, K.
    Cheilas, G.
    Banhazi, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S80 - S81
  • [46] DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS: KEY ELEMENT FOR COST-EFFECTIVENESS MODELLING
    Hummel, N.
    Gsteiger, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A704 - A705
  • [47] Do multiple sclerosis cost-effectiveness studies follow best practice guidelines? A review of 5 case studies
    Shafrin, Jason
    Kantor, Daniel
    Brauer, Michelle
    Ko, John
    Herrera, Vivian
    Goldman, Dana
    [J]. NEUROLOGY, 2017, 88
  • [48] Modelling cost-effectiveness in osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    [J]. BONE, 2008, 43 (01) : 215 - 216
  • [49] Modelling for cost-effectiveness analysis
    Russell, LB
    [J]. STATISTICS IN MEDICINE, 1999, 18 (23) : 3235 - 3244
  • [50] VALUE OF ADJUVANT ONCOLOGY THERAPIES: METHODOLOGICAL CHALLENGES OF MODELLING COST-EFFECTIVENESS OF AN ADJUVANT TREATMENT IN AN ERA OF HIGH-COST ONCOLOGY TREATMENTS
    Kovacs, V
    Kiss, Z.
    Tichy, E.
    Benedict, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S4 - S4
12345